This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a McGill University directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and the Prevention of Cirrhosis Among Patients With Type 2 Diabetes.
Diabetes care · 2025
Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study.
BMJ (Clinical research ed.) · 2024
Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes.
Diabetes care · 2022
Latest funding
- $497,250
Use of ultra-long-acting insulin versus long-acting insulin in the management of type 2 diabetes and the risk of adverse renal outcomes among people with diabetic kidney disease
CIHR · 2026 · Co-investigator
- $397,800
GLP-1 Receptor Agonists in Older Adults: Weighing Cardiovascular Benefits Against Frailty-Related Risks
CIHR · 2025 · Co-investigator
- $294,526
Assessing the long-term carcinogenic effects of glucagon-like peptide-1 receptor agonists on thyroid, pancreatic, and biliary tract cancers: an international, multi-site cohort study
CIHR · 2024 · Co-investigator
7 publications.
Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and the Prevention of Cirrhosis Among Patients With Type 2 Diabetes.
Pradhan R, Yin H, Lu S, Sebastiani G, Yu O, Suissa S, Azoulay L
Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study.
Simms-Williams N, Treves N, Yin H, Lu S, Yu O, Pradhan R, Renoux C, Suissa S, Azoulay L
Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes.
Pradhan R, Yin H, Yu O, Azoulay L
Long-Term patterns of cancer incidence among patients with and without type 2 diabetes in the United Kingdom.
Pradhan R, Yu O, Platt RW, Azoulay L
Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Severe Hypoglycemia.
Yu O, Azoulay L, Yin H, Filion KB, Suissa S
Reply to D. Tural et al.
Azoulay L, Yu O, Suissa S
Use of statins and the risk of death in patients with prostate cancer.
Yu O, Eberg M, Benayoun S, Aprikian A, Batist G, Suissa S, Azoulay L
Use of ultra-long-acting insulin versus long-acting insulin in the management of type 2 diabetes and the risk of adverse renal outcomes among people with diabetic kidney disease
Principal investigators: Filion, Kristian B
Keywords: Chronic Kidney Desease; Cohort Study; Comparative Effectiveness; Diabetic Kidney Disease; Dialysis; Insulin; Pharmacoepidemiology; Real-World Data; Renal Failure; Type 2 Diabetes
GLP-1 Receptor Agonists in Older Adults: Weighing Cardiovascular Benefits Against Frailty-Related Risks
Principal investigators: Azoulay, Laurent; Pradhan, Richeek
Keywords: Drug Effectiveness; Drug Safety; Frailty; Glp-1 Receptor Agonists; Older Patients; Population-Based; Type 2 Diabetes
Assessing the long-term carcinogenic effects of glucagon-like peptide-1 receptor agonists on thyroid, pancreatic, and biliary tract cancers: an international, multi-site cohort study
Principal investigators: Azoulay, Laurent
Keywords: Epidemiology; Health Intervention; Obesity; Population-Based; Type 2 Diabetes
The association between levothyroxine treatment and the risk of metabolic dysfunction-associated steatotic liver disease among people with subclinical hypothyroidism
Principal investigators: Yu, Oriana Hoi Yun
Keywords: Levothyroxine; Metabolic Dysfunction-Associated Steatotic Liver Disease; Pharmacoepidemiology; Population-Based Cohort Study; Subclinical Hypothyroidism
The association between denosumab and the risk of atypical femoral fractures in osteoporosis management
Principal investigators: Yu, Oriana Hoi Yun
Keywords: Atypical Femoral Fractures; Denosumab; Osteoporosis; Population Cohort Study
The Use of Incretin-Based Drugs and SGLT-2 Inhibitors for the Prevention of Parkinson's Disease Among Patients with Type 2 Diabetes
Principal investigators: Renoux, Christel; Azoulay, Laurent
Keywords: Cohort Study; Electronic Medical Records; Incretin-Based Drugs; Parkinson'S Disease; Pharmacoepidemiology; Sglt-2 Inhibitors
Comparative Effectiveness of Long-acting Insulins and Neutral Protamine Hagedorn (NPH) Insulin for the Prevention of Micro- and Macrovascular Complications Among Patients with Type 1 Diabetes
Principal investigators: Filion, Kristian B
Keywords: Cardiovascular Events; Cohort Study; Comparative Effectiveness; Insulin; Nephropathy; Neuropathy; Pharmacoepidemiology; Population Health; Retinopathy; Type 1 Diabetes
INSPEIR: International Study for the Prevention of Dementia with Incretin-based drugs
Principal investigators: Renoux, Christel; Azoulay, Laurent
Keywords: Cohort Study; Dementia; Electronic Medical Records; Incretin-Based Drugs; Pharmacoepidemiology
The Use of GLP-1 Receptor Agonists and SGLT-2 Inhibitors for the Long-term Prevention of Liver Complications Among Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
Principal investigators: Azoulay, Laurent
Keywords: Cirrhosis; Drug Effectiveness; Glp-1 Receptor Agonists; Hepatocellular Carcinoma; Non-Alcoholic Fatty Liver Disease; Population-Based; Sglt-2 Inhibitors; Type 2 Diabetes
Use of sodium glucose co-transporter-2 inhibitors and the risk of dementia
Principal investigators: Yu, Oriana Hoi Yun
Keywords: Diabetes; Pharmacoepidemiology; Sodium Glucose Cotransporter-2 Inhibitors
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Medicine
- Endocrinology and Metabolism
- Oncology
- Clinical Epidemiology
- Chemical Engineering
- Other
Co-authors at McGill University, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
Laurent Azoulay
Faculty
7 shared papers, latest 2025
Laurent Azoulay
Oncology
7 shared papers, latest 2025
Samy Suissa
Medicine
5 shared papers, latest 2025
Richeek Pradhan
Faculty
2 shared papers, latest 2022
Gerald Batist
Medicine
1 shared papers, latest 2014
Gerald Batist
Chemical Engineering
1 shared papers, latest 2014
Christel Renoux
Clinical Epidemiology
1 shared papers, latest 2024
Giada Sebastiani
Medicine
1 shared papers, latest 2025
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.